tiprankstipranks
Trending News
More News >
Dr. Reddy's Laboratories Ltd (RDY)
:RDY
US Market
Advertisement

Dr Reddy's Laboratories (RDY) Earnings Dates, Call Summary & Reports

Compare
444 Followers

Earnings Data

Report Date
Jan 23, 2026
Before Open (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
0.16
Last Year’s EPS
0.2
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Oct 24, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mixed performance with significant revenue growth in various markets and strategic acquisitions, contrasted by challenges in the U.S. generics market, regulatory hurdles, and decreased margins.
Company Guidance
During Dr. Reddy's Laboratories Q2 FY '26 earnings call, the company reported a consolidated revenue of INR 8,805 crores (USD 992 million), reflecting a 9.8% year-over-year increase and a 3% sequential growth. The EBITDA margin stood at 26.7%, with an underlying margin of 27.5% after adjusting for a one-time VAT provision. The SG&A expenses were INR 2,644 crores (USD 298 million), representing 30% of revenues, while R&D expenditure was INR 620 crores (USD 70 million), accounting for 7% of revenues. The net profit attributable to equity holders was INR 1,437 crores (USD 162 million), marking a 14% year-over-year growth. The company maintained a net cash surplus of INR 2,751 crores (USD 310 million) as of September 30, 2025. The management emphasized strategic growth through consumer healthcare integration, focus on key pipeline products like semaglutide and abatacept, and operational efficiencies to sustain long-term growth.
Revenue Growth Despite Challenges
Achieved a 9.8% year-over-year revenue growth, reaching USD 992 million, with support from the acquired consumer healthcare business and favorable Forex.
Emerging Markets Expansion
Emerging market revenue grew by 14% year-over-year and 18% sequentially, driven by new product launches and favorable Forex.
India Market Performance
India business reported a 13% year-over-year growth, driven by new product launches, improved pricing, and higher volumes.
Strategic Acquisitions and Partnerships
Acquired Stugeron brand in anti-vertigo segment and entered into partnerships for innovative therapies and biosimilars.
ESG Recognition
Retained MSCI ESG Rating of A and improved ESG Risk Rating from Morningstar Sustainalytics, demonstrating commitment to sustainability.

Dr Reddy's Laboratories (RDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RDY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jan 23, 2026
2026 (Q3)
0.16 / -
0.197
Oct 24, 2025
2026 (Q2)
0.19 / 0.20
0.17810.67% (+0.02)
Jul 29, 2025
2026 (Q1)
0.21 / 0.20
0.199-1.01% (>-0.01)
May 09, 2025
2025 (Q4)
0.21 / 0.22
0.18819.15% (+0.04)
Jan 23, 2025
2025 (Q3)
0.21 / 0.20
0.199-1.01% (>-0.01)
Nov 05, 2024
2025 (Q2)
0.21 / 0.18
0.213-16.43% (-0.04)
Jul 27, 2024
2025 (Q1)
0.19 / 0.20
0.206-3.40% (>-0.01)
May 07, 2024
2024 (Q4)
0.18 / 0.19
0.1434.29% (+0.05)
Jan 30, 2024
2024 (Q3)
0.18 / 0.20
0.1848.15% (+0.02)
Oct 27, 2023
2024 (Q2)
0.17 / 0.21
0.16231.48% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

RDY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 24, 2025
$14.62$14.58-0.27%
Jul 29, 2025
$14.70$14.76+0.41%
May 09, 2025
$13.11$13.33+1.68%
Jan 23, 2025
$15.01$14.08-6.20%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?
Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on Jan 23, 2026, Before Open (Confirmed).
    What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?
    Dr. Reddy's Laboratories Ltd (RDY) earnings time is at Jan 23, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RDY EPS forecast?
          RDY EPS forecast for the fiscal quarter 2026 (Q3) is 0.16.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis